[
  {
    "ts": null,
    "headline": "Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights",
    "summary": "More than 70% of surveyed U.S. ophthalmologists anticipate a fundamentally transformed approach to managing nAMD and DME within the next five years.Exton, Pennsylvania, July 10, 2025 (GLOBE NEWSWIRE) -- Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The Q2 wave of the syndicated RealTime Dynamix™ studies—based on",
    "url": "https://finnhub.io/api/news?id=5fb3d63c87d00a8b119171f4aa95b84e2b6e90c0f14b050d6a382f5142e27b8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752168420,
      "headline": "Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights",
      "id": 135866993,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "More than 70% of surveyed U.S. ophthalmologists anticipate a fundamentally transformed approach to managing nAMD and DME within the next five years.Exton, Pennsylvania, July 10, 2025 (GLOBE NEWSWIRE) -- Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The Q2 wave of the syndicated RealTime Dynamix™ studies—based on",
      "url": "https://finnhub.io/api/news?id=5fb3d63c87d00a8b119171f4aa95b84e2b6e90c0f14b050d6a382f5142e27b8c"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=d92748439fd8a4cafdbc15d51a1aabc805b33b5a25a81fb208e669c5cc323072",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752165960,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 135981340,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=d92748439fd8a4cafdbc15d51a1aabc805b33b5a25a81fb208e669c5cc323072"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Comes Out As ADA Winner",
    "summary": "Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will solidify its market dominance for the next 5-7 years. Read more.",
    "url": "https://finnhub.io/api/news?id=b71f4849eb54996b367f6072dd34788ba1aca254fdff35358faab0e56a11a865",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752165108,
      "headline": "Eli Lilly Comes Out As ADA Winner",
      "id": 135862272,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1355656320/image_1355656320.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will solidify its market dominance for the next 5-7 years. Read more.",
      "url": "https://finnhub.io/api/news?id=b71f4849eb54996b367f6072dd34788ba1aca254fdff35358faab0e56a11a865"
    }
  },
  {
    "ts": null,
    "headline": "MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial",
    "summary": "The study will assess ateganosine in individuals who have been heavily pre-treated in third-line (3L) NSCLC.",
    "url": "https://finnhub.io/api/news?id=46f60b59a182f076d6c3994642c549fca16c4ad6d83a8814ef5c79b41c252446",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752158441,
      "headline": "MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial",
      "id": 135856401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The study will assess ateganosine in individuals who have been heavily pre-treated in third-line (3L) NSCLC.",
      "url": "https://finnhub.io/api/news?id=46f60b59a182f076d6c3994642c549fca16c4ad6d83a8814ef5c79b41c252446"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025",
    "summary": "Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN stock is upgraded to buy.",
    "url": "https://finnhub.io/api/news?id=2495b4aff067e964fa9334b784dd6c51873da2d471928bb2c9a40098efee24f3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752138900,
      "headline": "Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025",
      "id": 135851366,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1336356688/image_1336356688.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN stock is upgraded to buy.",
      "url": "https://finnhub.io/api/news?id=2495b4aff067e964fa9334b784dd6c51873da2d471928bb2c9a40098efee24f3"
    }
  }
]